Viability & Biodistribution Study Service
Creative Biolabs provides the definitive evidence required to move your cell or gene therapy from the bench to the clinic. By characterizing the physiological fate of your therapeutic, we ensure you meet the rigorous expectations of global regulatory bodies while optimizing your dosing strategies. Our solutions empower you to identify sequestration risks in non-target organs (like the lung or brain) and validate the survival kinetics of your engineered cells. We offer specialized support for complex modalities, including "armored" CARs, TCR-T cells, and lipid nanoparticle (LNP) delivery systems.
Introduction of Viability and Biodistribution Studies
The transition from ex vivo cell engineering to in vivo efficacy is the most critical hurdle in modern immunotherapy. Biodistribution (BD) studies quantify the spatial and temporal distribution of administered products, while viability assessments measure the metabolic "fitness" of these cells post-administration. Research highlights that peak expansion kinetics and tissue accumulation are the primary predictors of therapeutic success. In vivo generation of CAR-T cells via LNPs or viral vectors represents a major shift, requiring even more precise tracking of transient vs. stable expression. By integrating molecular quantification with functional assays, Creative Biolabs provides a holistic view of cell fate.
Comprehensive Analytical Solutions
Our platform is designed to provide a 360-degree view of your therapeutic's behavior post-administration. We offer high-resolution molecular quantification and functional assessments tailored to your specific molecule.
Quantitative Molecular Tracking
Utilizing qPCR and digital PCR (dPCR) to detect DNA/RNA sequences with extreme sensitivity. This is essential for determining the persistence of viral vectors and the long-term presence of engineered cells in various tissues.
Functional Viability & Fitness Profiling
We go beyond simple survival counts by assessing metabolic flux (mitochondrial activity), membrane integrity (LDH/PI assays), and cytokine secretion profiles to ensure the cells remain therapeutically active in the suppressive tumor microenvironment.
Multi-Modal In Vivo Imaging
Real-time tracking of cell migration and tissue accumulation using PET, SPECT, and high-field MRI. This provides longitudinal data without the need for terminal sampling at every time point.
Immunogenicity and Safety Evaluation
Monitoring for systemic inflammatory responses and potential off-target integration to provide a complete safety profile.
Explore Our Full Range of Offerings - Inquire for Technical Details
Workflow
At Creative Biolabs, our workflow is engineered to be transparent and rigorous, ensuring that every variable, from administration route to the sensitivity of detection, is optimized for your unique therapeutic candidate.
Publication
This study presents a novel fourth-generation lentiviral vector platform for in vivo CAR T cell generation. The authors developed CD3- or CD8-targeted vectors using a mixed Nipah envelope with binders, achieving specific and efficient T cell transduction. The SupA2KO-LV genome incorporates the TRiP system to prevent CAR protein packaging. Intravenous injection into humanized mice generated high levels of functional CAR T cells, inducing rapid and sustained B cell aplasia with minimal off-target transduction.
Fig.1 Rapid in vivo CAR T cell generation using targeted fourth-generation lentiviral vectors. 1
Why Choose Us
Creative Biolabs offers unparalleled technical depth, having managed hundreds of complex studies for various modalities including CAR-T, TCR-T, and LNP-mRNA systems. Our unique "fitness" metrics go beyond simple survival, providing a metabolic and functional profile of your cells. We adhere to international standards, ensuring that our data stands up to scrutiny from major global regulatory agencies. Our expertise in handling human-origin cells in immunodeficient models ensures that your results are highly predictive of clinical performance.
Experience the Creative Biolabs Advantage - Get a Quote Today
FAQs
What is the limit of detection (LOD) for your dPCR tracking?
Our dPCR platforms are highly sensitive, often reaching detection levels as low as 0.01% or single-digit copy numbers per microgram of DNA.
Do you offer studies for "In Vivo" CAR-T generation?
Yes, we provide specialized LNP tracking and transient expression monitoring for in situ engineering platforms.
How do you handle "living drug" survival assessment?
We use a multi-modal approach combining membrane integrity, metabolic flux, and functional motility assays to ensure cells are fit for the TME.
Customer Review
-
Exceptional Sensitivity
Using Creative Biolabs' dPCR platform in our research has significantly improved our ability to track low-copy-number integration in bone marrow samples. - Dr. J***n S****h -
Innovative Fitness Metrics
Our research into metabolic reprogramming was facilitated by their unique metabolic flux assays, which proved our cells remained active in acidic environments. - Prof. Mi****l K****r
Related Services
Oncolytic Virus (OV) Therapy Discovery Service
Creative Biolabs provides end-to-end OV development, including genetic engineering, in vivo validation, and manufacturing. We optimize viral-mediated tumor lysis and therapeutic gene insertion to trigger potent, systemic antitumor immunity.
Learn More →Engineering Melanoma Cells for Self-destruction
Creative Biolabs provides advanced melanoma therapy development, focusing on targeted kinase inhibitors and engineered oncolytic viruses. We optimize GM-CSF delivery to trigger systemic T-cell responses and overcome tumor heterogeneity.
Learn More →Contact Us
Creative Biolabs provides a specialized, data-driven foundation for your cell and gene therapy programs. From mapping the intricate journey of an LNP to validating the long-term survival of a CAR-T product, our team ensures your lead is ready for the clinic. We bridge the gap between early discovery and regulatory success with precision and expertise.
For detailed project discussions and technical inquiries, please reach out to our specialist team. We are committed to providing the scientific rigor your project deserves.
Reference
- Coradin, T., et al. "Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector." Mol Ther 33.10 (2025): 4953-67. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1016/j.ymthe.2025.07.006
Download our brochure